AI Article Synopsis

  • The study aimed to compare overall and cancer-specific survival rates after robotic-assisted radical prostatectomy (RARP) versus radiation therapy (RT) for non-metastatic prostate cancer in patients aged 75 and older.
  • Researchers analyzed data from 1,110 patients treated at seven hospitals, using techniques to account for biases related to treatment choices.
  • Results showed that both RARP and RT offered similar survival outcomes, suggesting that choice of local treatment may not significantly impact survival rates, but future research should consider the potential side effects of these treatments.

Article Abstract

Purpose: To compare overall survivals (OSs) and cancer-specific survivals (CSSs) after robotic-assisted radical prostatectomy (RARP) and radiation therapy (RT), the latter of which has long been recommended primarily for elderly patients (≥75 years) with non-metastatic prostate cancer (PCa), given the Korean male life span of 79.7 years (2018).

Materials And Methods: Retrospective data for aged ≥75 years who underwent RARP or RT at seven tertiary hospitals were analyzed. To account for indication-related bias, inverse probability of treatment-weighting (IPTW) was applied before and after Cox regression.

Results: Of the 1,110 study subjects, 883 underwent RARP and 227 RT from 2007 to 2016. The differences between groups including the age (≥80 y; 25.4% vs. 32.8%; p=0.034), concomitant diabetes (14.9% vs. 22.9%; p=0.007), coronary heart disease (3.5% vs. 7.5%; p=0.015), and PCa risk stratification (high-risk; 18.2% vs. 59.7%; p<0.001) were balanced after IPTW. During a mean follow-up of 74.5 months, OSs (91.9% vs. 91.0%) and CSSs (97.8% vs. 98.0%) were similar. After IPTW, overall mortality was associated with diabetes (hazard ratio [HR], 2.273; p<0.0001) and inversely with low-risk PCa (HR, 0.314; p<0.0001), the last of which was solely associated with cancer-specific mortality (HR, 0.245; p=0.0005). The implementation of local treatment between RARP and RT demonstrated no impact on survival, for whole and high-risk populations.

Conclusions: Even aged over 75 years, patients who underwent RARP for non-metastatic PCa had similar survival with RT regardless of risk stratification. However, the survival needs to be weighed with the morbidity of local treatment in a future study.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421997PMC
http://dx.doi.org/10.4111/icu.20210079DOI Listing

Publication Analysis

Top Keywords

robotic-assisted radical
8
radical prostatectomy
8
radiation therapy
8
years non-metastatic
8
non-metastatic prostate
8
prostate cancer
8
≥75 years
8
underwent rarp
8
comparison survival
4
survival outcomes
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!